catequentinib

Overview

Catequentinib (marketed and widely studied under the name anlotinib; also known as AL3818) is a novel, orally administered small-molecule multi-target tyrosine kinase inhibitor (TKI) with broad antitumor activity. It exerts its pharmacological effects by simultaneously blocking multiple receptor tyrosine kinases involved in tumor angiogenesis, proliferation, and survival, including vascular endothelial growth factor receptors (VEGFRs), fibroblast growth factor receptors (FGFRs), platelet-derived growth factor receptors (PDGFRs), and c-Kit. By concurrently inhibiting these overlapping signaling axes, catequentinib disrupts tumor neovascularization and directly suppresses tumor cell proliferation, offering a mechanistic rationale for its use across a broad spectrum of solid malignancies.

As a multi-target agent, catequentinib occupies a distinct niche within the TKI class. Unlike single-target inhibitors such as gefitinib or osimertinib — which are designed around specific oncogenic driver mutations — catequentinib's broader receptor profile makes it applicable to tumor types that lack a single dominant driver alteration. This characteristic has driven its investigation in diseases including lung cancer, osteosarcoma, colorectal cancer, endometrial cancer, and others, frequently in combination with immune checkpoint inhibitors or cytotoxic chemotherapy agents.

Recent Publications Summary

Recent publications have continued to evaluate catequentinib, most often in combination regimens across a range of solid tumors. In a multicenter, single-arm phase 2 trial in advanced bone and soft tissue sarcomas, including ultra-rare sarcomas, catequentinib plus toripalimab produced a confirmed objective response rate of 29%, a disease control rate of 90%, median progression-free survival of 7.0 months, and median overall survival of 27.0 months; in soft-tissue ultra-rare sarcomas, the response rate was 39% and median progression-free survival was 11.0 months 42258994Jun. Treatment-related grade ≥3 adverse events in that study included hypertension, hand-foot syndrome, and hypertriglyceridemia 42258994Jun.

In lung cancer, catequentinib has been studied in several settings. A prospective phase II trial evaluated tislelizumab plus catequentinib as first-line therapy for advanced pulmonary sarcomatoid carcinoma 41894181Mar, and another phase 3 study compared benmelstobart plus catequentinib with pembrolizumab in previously untreated, driver gene-negative, PD-L1-positive advanced non-small-cell lung cancer 41825453Mar. Catequentinib has also been investigated as maintenance therapy with toripalimab in extensive-stage small cell lung cancer after disease control with platinum-etoposide chemotherapy, with the study also exploring a preclinical mechanism involving suppression of neuroendocrine differentiation via Notch1 41825180Mar. In addition, a real-world pharmacovigilance analysis of anti-NSCLC drugs included catequentinib and reported that skin/subcutaneous tissue disorders and gastrointestinal disorders were common system-organ-class signals across the evaluated agents 42175505May.

Other recent reports extended catequentinib into additional malignancies and treatment strategies. A retrospective study in chemotherapy-refractory osteosarcoma found that catequentinib combined with limb salvage surgery was associated with a longer median progression-free survival than surgery alone 42175488May. A phase II study in refractory metastatic colorectal cancer evaluated catequentinib with trifluridine-tipiracil as a third-line approach 41719193Feb. In glioblastoma, a single-arm phase 2 study assessed postoperative catequentinib plus radiotherapy in newly diagnosed unmethylated MGMT glioblastoma 42339996Jun. A case report also described catequentinib combined with envafolimab as neoadjuvant therapy in chemotherapy-refractory advanced endometrial cancer, leading to rapid symptom improvement, marked tumor regression, and conversion to surgery with R0 resection 42077092May.

Preclinical and formulation studies have further explored catequentinib-based strategies. One nanomedicine study developed a catequentinib-loaded heterogeneous inorganic delivery system for non-small-cell lung cancer, reporting enhanced tumor targeting, increased reactive oxygen species, modulation of ferroptosis-related proteins including Cyclooxygenase 2 (COX-2), and stronger antitumor activity than free catequentinib in cell and xenograft models 41795318Mar. Together, these publications portray catequentinib as a broadly investigated anti-angiogenic therapy being paired with immunotherapy, radiotherapy, chemotherapy, surgery, and novel delivery platforms across multiple tumor types 42258994Jun41894181Mar41825453Mar41825180Mar42175488May41719193Feb42339996Jun42077092May41795318Mar.

What Changes, What Holds

1. Catequentinib is emerging as a credible combination partner in rare sarcomas, but the signal remains early and regimen-specific
NEW DIRECTION A broader role beyond the Overview’s general antitumor framing is suggested here: catequentinib is not just being tested across solid tumors, but is showing activity in ultra-rare sarcoma settings where options are limited 42258994Jun. The main implication is not a change in mechanism, but a stronger case for disease-specific combination development. Toxicities such as hypertension and hand-foot syndrome remain consistent with its anti-angiogenic profile.

2. Lung-cancer development is moving from exploratory use toward head-to-head and maintenance strategies
REINFORCES Recent lung-cancer studies do not alter the established account that catequentinib is being pursued broadly in solid tumors; they sharpen that picture by showing it is being positioned in multiple treatment lines and histologies 41894181Mar41825453Mar. The maintenance study in small-cell disease also extends the drug into post-induction control rather than only upfront treatment, while the pharmacovigilance signal mainly adds safety context rather than new biology 42175505May.

3. Catequentinib is being pushed into salvage, perioperative, and post-radiation settings across additional Cancers
NEW DIRECTION These reports broaden the Overview’s “investigated in” language into more specific clinical roles: surgery-adjacent use in osteosarcoma, third-line therapy in colorectal cancer, postoperative treatment in glioblastoma, and neoadjuvant conversion therapy in endometrial cancer 42175488May41719193Feb. None of this overturns the baseline, but it does show the drug is being explored as a multimodal adjunct rather than only a systemic antitumor agent.

4. Formulation work suggests catequentinib may be paired with ferroptosis-oriented delivery, but this is still preclinical
METHOD The nanomedicine study changes how catequentinib is being delivered and studied, not what is yet established clinically 41795318Mar. Its value is in showing a platform that may intensify tumor targeting and cell-death pathways in models of non-small-cell lung cancer. That is hypothesis-generating rather than practice-changing, and it does not challenge the Overview’s core description of catequentinib as a multi-target TKI.

Overview update candidates: none.